## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (cancelled)
- 2. (currently amended) An isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:111, with the exception that the polypeptide contains an amino acid change which results from a single nucleotide polymorphism of guanine to adenine at position 21 set forth in SEQ ID NO.: 5969.
- 3-4. (cancelled)
- 5. (currently amended) An isolated nucleic acid comprising a nucleotide sequence of SEQ ID NO.:19, with the exception that the nucleic acid contains a single nucleotide polymorphism of guanine to adenine at position 21 of SEQ ID NO.: 5969.
- 6-10. (cancelled)
- 11. (previously presented)An isolated nucleic acid comprising a nucleotide sequence which is complementary to the nucleotide sequence of the nucleic acid according to claim 5.
- 12-14. (cancelled)
- 15. (previously presented) A vector comprising the nucleic acid according to claim 2.
- 16. (previously presented) A vector comprising the nucleic acid according to claim 5.
- 17. (cancelled)

- 18. (currently amended) An isolated host cell comprising the vector according to claim 15, wherein the host cell is selected from the group consisting of <u>a</u> bacterial <u>cell</u>, <u>a</u> yeast <u>cell</u>, <u>an insect cell</u>, <u>a mammalian cell</u>, and <u>a plant celleells</u>.
- 19. (currently amended) An isolated host cell comprising the vector according to claim 16, wherein the host cell is selected from the group consisting of <u>a</u> bacterial <u>cell</u>, <u>a</u> yeast <u>cell</u>, <u>an insect cell</u>, <u>a mammalian cell</u>, and <u>a plant cellcells</u>.

20-30. (cancelled)

- 31. (currently amended) A pharmaceutical composition comprising the nucleic acid according to claim 11, and a physiologically acceptable carrier, excipient, or diluent.

  32-33. (cancelled)
- 34. (currently amended) A pharmaceutical composition comprising the vector according to claim 15, and a physiologically acceptable carrier, excipient, or diluent.
- 35. (currently amended) A pharmaceutical composition comprising the vector according to claim 16, and a physiologically acceptable carrier, excipient, or diluent.

  36-55. (cancelled)
- 56. (previously presented) A kit for detecting a 12q23-qter nucleotide sequence comprising:
- a) the isolated nucleic acid according to claim 2; and
- b) at least one component to detect hybridization of the isolated nucleic acid to a 12q23-qter nucleotide sequence.
- 57. (previously presented) A kit for detecting a 12q23-qter nucleotide sequence comprising:
- a) the isolated nucleic acid according to claim 5; and

- b) at least one component to detect hybridization of the isolated nucleic acid to a 12q23-qter nucleotide sequence.
- 58. (cancelled)
- 59. (previously presented) A kit for detecting a 12q23-qter nucleotide sequence comprising:
- a) the isolated nucleic acid according to claim 11; and
- b) at least one component to detect hybridization of the isolated nucleic acid to a 12q23-qter nucleotide sequence.
- 60-125. (cancelled)